144 related articles for article (PubMed ID: 18294289)
1. Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.
Hagiwara Y; Hamada Y; Kuwahara M; Maeda M; Segawa T; Ishikawa K; Hino O
Cancer Sci; 2008 Apr; 99(4):666-70. PubMed ID: 18294289
[TBL] [Abstract][Full Text] [Related]
2. Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.
Sato T; Suzuki Y; Mori T; Maeda M; Abe M; Hino O; Takahashi K
Cancer Med; 2014 Oct; 3(5):1377-84. PubMed ID: 25045139
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic biomarker of asbestos-related mesothelioma: example of translational research.
Okio H; Kazu S; Masahiro M
Cancer Sci; 2007 Aug; 98(8):1147-51. PubMed ID: 17532755
[TBL] [Abstract][Full Text] [Related]
4. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
[TBL] [Abstract][Full Text] [Related]
5. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
Maeda M; Hino O
Pathol Int; 2006 Nov; 56(11):649-54. PubMed ID: 17040286
[TBL] [Abstract][Full Text] [Related]
6. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.
Shiomi K; Miyamoto H; Segawa T; Hagiwara Y; Ota A; Maeda M; Takahashi K; Masuda K; Sakao Y; Hino O
Cancer Sci; 2006 Sep; 97(9):928-32. PubMed ID: 16776777
[TBL] [Abstract][Full Text] [Related]
7. Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.
Ishikawa K; Segawa T; Hagiwara Y; Maeda M; Abe M; Hino O
Pathol Int; 2009 Mar; 59(3):161-6. PubMed ID: 19261093
[TBL] [Abstract][Full Text] [Related]
8. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
Segawa T; Hagiwara Y; Ishikawa K; Aoki N; Maeda M; Shiomi K; Hino O
Biochem Biophys Res Commun; 2008 May; 369(3):915-8. PubMed ID: 18328258
[TBL] [Abstract][Full Text] [Related]
9. Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin.
Nakaishi M; Kajino K; Ikesue M; Hagiwara Y; Kuwahara M; Mitani H; Horikoshi-Sakuraba Y; Segawa T; Kon S; Maeda M; Wang T; Abe M; Yokoyama M; Hino O
Cancer Sci; 2007 May; 98(5):659-64. PubMed ID: 17425688
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo.
Inami K; Abe M; Takeda K; Hagiwara Y; Maeda M; Segawa T; Suyama M; Watanabe S; Hino O
Cancer Sci; 2010 Apr; 101(4):969-74. PubMed ID: 20100205
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
Mundt F; Nilsonne G; Arslan S; Csürös K; Hillerdal G; Yildirim H; Metintas M; Dobra K; Hjerpe A
PLoS One; 2013; 8(8):e72030. PubMed ID: 23991032
[TBL] [Abstract][Full Text] [Related]
12. Serum level of expressed in renal carcinoma (ERC)/ mesothelin in rats with mesothelial proliferative lesions induced by multi-wall carbon nanotube (MWCNT).
Sakamoto Y; Dai N; Hagiwara Y; Satoh K; Ohashi N; Fukamachi K; Tsuda H; Hirose A; Nishimura T; Hino O; Ogata A
J Toxicol Sci; 2010 Apr; 35(2):265-70. PubMed ID: 20371980
[TBL] [Abstract][Full Text] [Related]
13. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
Inami K; Kajino K; Abe M; Hagiwara Y; Maeda M; Suyama M; Watanabe S; Hino O
Oncol Rep; 2008 Dec; 20(6):1375-80. PubMed ID: 19020717
[TBL] [Abstract][Full Text] [Related]
14. Blood tests for asbestos-related mesothelioma.
Maeda M; Hino O
Oncology; 2006; 71(1-2):26-31. PubMed ID: 17344668
[TBL] [Abstract][Full Text] [Related]
15. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
17. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma.
Tajima K; Hirama M; Shiomi K; Ishiwata T; Yoshioka M; Iwase A; Iwakami S; Yamazaki M; Toba M; Tobino K; Sugano K; Ichikawa M; Hagiwara Y; Takahashi K; Hino O
Anticancer Res; 2008; 28(6B):3933-6. PubMed ID: 19192652
[TBL] [Abstract][Full Text] [Related]
18. Bisecting-GlcNAc on Asn388 is characteristic to ERC/mesothelin expressed on epithelioid mesothelioma cells.
Fujihira H; Takakura D; Matsuda A; Abe M; Miyazaki M; Nakagawa T; Kajino K; Denda-Nagai K; Noji M; Hino O; Irimura T
J Biochem; 2021 Oct; 170(3):317-326. PubMed ID: 33792699
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
